The first in human clinical study is planned as an open-label, dose-escalation, and
dose-expansion, multicentre, two-part, Phase 1/2a study of PBP1510 administered to patients
with advanced/metastatic pancreatic cancer. The study will be conducted in two parts, Part 1
as a PBP1510 single agent dose-escalation, and PBP1510 dose-escalation in combination with
gemcitabine, and Part 2 as PBP1510 dose-expansion at the RP2D in combination with
gemcitabine.